Tri-specific killer cell engagers (TriKEs) targeting NK cells through their activating receptors, Nkp46 and CD16, together with a tumor antigen on the neoplastic cells, also constitutes a new generation of synthetic molecules for cancer immunotherapy. Here, NCR1 is linked to neoplasm.